05:49 AM EST, 11/21/2025 (MT Newswires) -- Inhibikase Therapeutics ( IKT ) said late Thursday that it priced its underwritten public offering of about 46.1 million common shares at $1.45 each and pre-funded warrants to buy about 22.9 million common shares at $1.449 each, for total expected gross proceeds of about $100 million.

The company also granted the underwriters a 30-day option to buy up to an additional about 10.3 million common shares. The offering is expected to close on Monday.

Inhibikase shares were up more than 13% in recent Friday premarket activity.